These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 17439183)

  • 21. [Treatment of HIV-infection by means of gene therapy].
    Glazkova DV; Bogoslovskaia EV; Markelov ML; Shipulin GA; Pokrovskiĭ VV
    Vestn Ross Akad Med Nauk; 2012; (5):16-23. PubMed ID: 22856163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Viral dynamics in the course of HIV-1 infection: pathogenetic features and new therapeutic prospects].
    Marcello A; Giacca M
    Pathologica; 2000 Aug; 92(4):291-3. PubMed ID: 11029891
    [No Abstract]   [Full Text] [Related]  

  • 23. Progress and challenges in the use of latent HIV-1 reactivating agents.
    Shang HT; Ding JW; Yu SY; Wu T; Zhang QL; Liang FJ
    Acta Pharmacol Sin; 2015 Aug; 36(8):908-16. PubMed ID: 26027656
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Can HIV be eradicated?
    Pantaleo G; Perrin L
    AIDS; 1998; 12 Suppl A():S175-80. PubMed ID: 9633000
    [No Abstract]   [Full Text] [Related]  

  • 25. HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir.
    Chun TW; Nickle DC; Justement JS; Large D; Semerjian A; Curlin ME; O'Shea MA; Hallahan CW; Daucher M; Ward DJ; Moir S; Mullins JI; Kovacs C; Fauci AS
    J Clin Invest; 2005 Nov; 115(11):3250-5. PubMed ID: 16276421
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Latency and reservoirs for HIV-1.
    Siliciano RF
    AIDS; 1999; 13 Suppl A():S49-58. PubMed ID: 10885762
    [No Abstract]   [Full Text] [Related]  

  • 27. The search for a cure for persistent HIV reservoirs.
    Lafeuillade A; Stevenson M
    AIDS Rev; 2011; 13(2):63-6. PubMed ID: 21587339
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Carbohydrate-binding agents (CBAs) inhibit HIV-1 infection in human primary monocyte-derived macrophages (MDMs) and efficiently prevent MDM-directed viral capture and subsequent transmission to CD4+ T lymphocytes.
    Pollicita M; Schols D; Aquaro S; Peumans WJ; Van Damme EJ; Perno CF; Balzarini J
    Virology; 2008 Jan; 370(2):382-91. PubMed ID: 17928023
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Control of HIV despite the discontinuation of antiretroviral therapy.
    Lisziewicz J; Rosenberg E; Lieberman J; Jessen H; Lopalco L; Siliciano R; Walker B; Lori F
    N Engl J Med; 1999 May; 340(21):1683-4. PubMed ID: 10348681
    [No Abstract]   [Full Text] [Related]  

  • 30. [HIV infection. Virus resistance: development and prevention].
    Link R; Miller V; Fätkenheuer G; Manegold C; Harrer T
    Med Monatsschr Pharm; 1999 Mar; 22(3):86-8. PubMed ID: 10223868
    [No Abstract]   [Full Text] [Related]  

  • 31. HIV replication.
    Kingman S
    Mol Med Today; 1995 Apr; 1(1):2. PubMed ID: 9415128
    [No Abstract]   [Full Text] [Related]  

  • 32. Why HIV drug resistance matters: an overview.
    Learned J
    Posit Aware; 2005; 16(5):26-30. PubMed ID: 16220604
    [No Abstract]   [Full Text] [Related]  

  • 33. A primer on HIV/AIDS.
    JCN
    J Christ Nurs; 2007; 24(1):14-6; quiz 17-8. PubMed ID: 17283817
    [No Abstract]   [Full Text] [Related]  

  • 34. Slow accumulation of HIV resistance mutations: implications for resource-limited settings?
    Stevens WS
    J Infect Dis; 2009 Sep; 200(5):670-2. PubMed ID: 19604045
    [No Abstract]   [Full Text] [Related]  

  • 35. HIV suppression and risk of drug resistance mutations.
    Phillips AN; Loveday C; Johnson MA
    AIDS; 1998 Oct; 12(14):1930. PubMed ID: 9792396
    [No Abstract]   [Full Text] [Related]  

  • 36. Enhancement of anti-HIV-1 activity by hot spot evolution of RANTES-derived peptides.
    Secchi M; Longhi R; Vassena L; Sironi F; Grzesiek S; Lusso P; Vangelista L
    Chem Biol; 2012 Dec; 19(12):1579-88. PubMed ID: 23261601
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV susceptibility testing--time for standards.
    Hill AM; Telenti A
    Antivir Ther; 2004 Aug; 9(4):463-4. PubMed ID: 15456076
    [No Abstract]   [Full Text] [Related]  

  • 38. Can HIV infection be eradicated through use of potent antiviral agents?
    Josefsson L; Dahl V; Palmer S
    Curr Opin Infect Dis; 2010 Dec; 23(6):628-32. PubMed ID: 20847693
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HIV-1 dynamics in vivo.
    Ho DD
    J Biol Regul Homeost Agents; 1995; 9(3):76-7. PubMed ID: 8782010
    [No Abstract]   [Full Text] [Related]  

  • 40. Is HIV infection a TNF receptor signalling-driven disease?
    Herbein G; Khan KA
    Trends Immunol; 2008 Feb; 29(2):61-7. PubMed ID: 18178131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.